PHARMA ONLINE WHITE PAPERS

• FDA's Regenerative Medicine Advanced Therapy (RMAT) Program

  RMAT qualification requires preliminary clinical evidence demonstrating the potential to address an unmet medical need. This designation grants benefits like intensive guidance and faster FDA review.

• Open-Label Study Assessing Relative And Absolute Bioavailability

  1/26/2026

  Consistent absorption across different formulations and dietary conditions ensures stable therapeutic exposure. This flexibility simplifies patient dosing schedules and supports manufacturing transitions.

• Why Tailored CDMO Support Is A Non-Negotiable In Sterile Fill-Finish

  4/13/2026

  Modern injectable programs require adaptable manufacturing strategies. Learn how flexibility, technical depth, and collaboration reduce complexity, manage change, and protect long‑term supply.

• Providing Enhanced Manufacturing Data To Contracting Companies

  2/12/2025

  The life sciences sector is projected to reach $220 billion by 2030. Examine the growth of CDMOs and CMOs, emphasizing the need for digitalization to meet client demands and regulatory standards.

• Make Your Production Sites Adaptable And More Efficient

  12/12/2025

  Pharma faces mounting complexity and tighter margins, demanding agile, future-ready production. Discover how smart manufacturing enables faster adaptation and continuous therapy availability.

• Benefits Of Single-Use Isolators For Cytotoxic Payload Handling

  6/15/2026

  Managing cytotoxic ADC payloads in shared containment facilities creates mounting compliance, safety, and operational costs that single-use isolator technology is designed to address.